Lactiplantibacillus plantarum strains KABP011, KABP012, and KABP013 modulate bile acids and cholesterol metabolism in humans.

Autor:	Padro T; Cardiovascular Program-ICCC, Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), Sant Antoni Mª Claret 167, Barcelona 08025, Spain.; Centro de Investigación Biomédica en Red Cardiovascular (CIBER-CV), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain., Santisteban V; Cardiovascular Program-ICCC, Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), Sant Antoni Mª Claret 167, Barcelona 08025, Spain.; School of Pharmacy and Food Sciences, University of Barcelona (UB), Barcelona, Spain., Huedo P; R&D Department, AB-Biotics S.A. (Part of Kaneka Corporation), Barcelona, Spain.; Basic Sciences Department, Universitat Internacional de Catalunya, Barcelona, Spain., Puntes M; Medicament Research Center (CIM), Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), Barcelona, Spain., Aguiló M; R&D Department, AB-Biotics S.A. (Part of Kaneka Corporation), Barcelona, Spain., Espadaler-Mazo J; R&D Department, AB-Biotics S.A. (Part of Kaneka Corporation), Barcelona, Spain., Badimon L; Cardiovascular Program-ICCC, Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), Sant Antoni Mª Claret 167, Barcelona 08025, Spain.; Centro de Investigación Biomédica en Red Cardiovascular (CIBER-CV), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Cardiovascular Research Chair, Universitat Autònoma de Barcelona, Plaça Cívica, 08193 Bellaterra, Barcelona, Spain.
Jazyk:	angličtina
Zdroj:	Cardiovascular research [Cardiovasc Res] 2024 May 29; Vol. 120 (7), pp. 708-722.
DOI:	10.1093/cvr/cvae061
Abstrakt:	Aims: Probiotics with high bile salt hydrolase (BSH) activity have shown to promote cardiovascular health. However, their mechanism(s) of action remain poorly understood. Here, we performed a pilot exploratory study to investigate effects of a 4-week intervention with escalating doses of a BSH-active formula containing Lactiplantibacillus plantarum strains KABP011, KABP012, and KABP013 on bile acid (BA), lipid profile, and lipoprotein function. Methods and Results: Healthy overweight individuals were included in this study. The probiotic intake was associated with a progressive decrease of conjugated BAs in serum, due to the reduction of tauro- and glyco-conjugated forms. Plasma levels of fibroblast growth factor-19 were significantly reduced and correlated with BA changes. The probiotic induced significant changes in serum lipids, with reduction in non-HDL cholesterol (non-HDLc) and LDL cholesterol (LDLc) levels. The largest decrease was evidenced in the subgroup with higher baseline LDLc levels (LDLc > 130 mg/dL). Fasting levels of circulating apolipoprotein(Apo) B100 and ApoB48 were significantly reduced. Importantly, the decrease in non-HDLc levels was associated with a significant reduction in small LDL particles. Functional testing indicated that LDL particles had a significantly lower susceptibility to oxidation, while HDL particles gained antioxidant capacity after the probiotic intake. The microbiota profile in faeces collected at the end of the study was enriched with members of class Desulfovibrio, a taurine-consuming bacteria, likely because of the increase in free taurine in the gut due to the BSH activity of the probiotic. Conclusion: The intervention with L. plantarum strains induces beneficial effects on BA signature and lipoprotein profile. It reduces ApoB and small LDL levels and LDL susceptibility to oxidation and increases HDL antioxidant capacity. These metabolic profile changes suggest increased protection against atherosclerotic disease. Competing Interests: Conflict of interest L.B. declares to have acted as an SAB member of Sanofi, Ionnis, MSD, and Novo Nordisk; to have a research grant from AstraZeneca; to have received speaker fees from Sanofi, Bayer, and AB-Biotics SA; and to have founded the spin-off Ivastatin Therapeutics S.L. (all unrelated to this work). T.P. declares to have received speaker fees from AB-Biotics SA and to be a co-founder of the spin-off Ivastatin Therapeutics S.L. (all unrelated to this work). P.H., M.A., and J.E.-M. are currently employees of AB-Biotics S.A. (part of KANEKA Corporation). (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu